Imidazo[1,2-b]pyridazine as privileged scaffold in medicinal chemistry: An extensive review.
Anti-inflammatory
Antibacterial
Anticancer
Antiparasitic
Antiviral
Biological activities
Imidazo[1,2-b]pyridazine
Metabolic disorders
Radiotracers
Sleeping disorders
Structure-activity relationship
Thymic enhancers
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
15 Dec 2021
15 Dec 2021
Historique:
received:
28
06
2021
revised:
09
09
2021
accepted:
20
09
2021
pubmed:
5
10
2021
medline:
27
1
2022
entrez:
4
10
2021
Statut:
ppublish
Résumé
Imidazo[1,2-b]pyridazine scaffold represents an important class of heterocyclic nucleus which provides various bioactives molecules. Among them, the successful kinase inhibitor ponatinib led to a resurgence of interest in exploring new imidazo[1,2-b]pyridazine-containing derivatives for their putative therapeutic applications in medicine. This present review intends to provide a state-of-the-art of this framework in medicinal chemistry from 1966 to nowadays, unveiling different aspects of its structure-activity relationships (SAR). This extensive literature surveil may guide medicinal chemists for the quest of novel imidazo[1,2-b]pyridazine compounds with enhanced pharmacokinetics profile and efficiency.
Identifiants
pubmed: 34607244
pii: S0223-5234(21)00716-9
doi: 10.1016/j.ejmech.2021.113867
pii:
doi:
Substances chimiques
Anti-Infective Agents
0
Anti-Inflammatory Agents
0
Antineoplastic Agents
0
Pyridazines
0
imidazo(1,2-b)pyridazine
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
113867Informations de copyright
Copyright © 2021. Published by Elsevier Masson SAS.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.